Lineage Cell Therapeutics, Inc.
For the period ended Aug 6, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 6, 2026 · Filed Aug 6, 2026
Use the contents to explore the available documents and sections.
LCTX$1.02+3.8%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (IN THOUSANDS, EXCEPT PER SHARE DATA)
(IN THOUSANDS, EXCEPT PER SHARE DATA)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| REVENUES: | ||||
| Collaboration revenues | $943 | $2,532 | $2,518 | $3,802 |
| Royalties, license and other revenues | 126 | 233 | 276 | 465 |
| Total revenues | 1,069 | 2,765 | 2,794 | 4,267 |
| OPERATING EXPENSES: | ||||
| Cost of royalties | — | 39 | — | 75 |
| Research and development | 4,774 | 3,106 | 9,008 | 6,220 |
| General and administrative | 5,218 | 4,560 | 10,302 | 9,417 |
| Loss on impairment of intangible asset | — | 14,840 | — | 14,840 |
| Total operating expenses | 9,992 | 22,545 | 19,310 | 30,552 |
| Loss from operations | (8,923) | (19,780) | (16,516) | (26,285) |
| OTHER INCOME (EXPENSES): | ||||
| Interest income, net | 378 | 454 | 783 | 932 |
| Gain (loss) on marketable equity securities, net | — | (2) | 24 | (7) |
| Change in fair value of warrant liability | 9,443 | (12,740) | 11,767 | (10,435) |
| Foreign currency transaction gain, net | 664 | 1,678 | 714 | 1,447 |
| Other income (expense), net | (18) | 26 | (17) | (159) |
| Total other income (expenses) | 10,467 | (10,584) | 13,271 | (8,222) |
| NET INCOME (LOSS) | 1,544 | (30,364) | (3,245) | (34,507) |
| Net (income) loss attributable to noncontrolling interest | (62) | (100) | (85) | (96) |
| NET INCOME (LOSS) ATTRIBUTABLE TO LINEAGE | $1,482 | $(30,464) | $(3,330) | $(34,603) |
| NET INCOME (LOSS) PER COMMON SHARE ATTRIBUTABLE TO LINEAGE: | ||||
| Basic | $0.01 | $(0.13) | $(0.01) | $(0.15) |
| Diluted | $(0.03) | $(0.13) | $(0.06) | $(0.15) |
| WEIGHTED-AVERAGE COMMON SHARES USED TO COMPUTE NET INCOME (LOSS) PER COMMON SHARE: | ||||
| Basic | 249,499 | 228,356 | 247,276 | 227,212 |
| Diluted | 261,471 | 228,356 | 261,524 | 227,212 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.